Mesothelioma - Intravascular injection of thorium dioxide (Thorotrast) Factor
Last reviewed for CCPS 15 October 2008.
Preliminary questions [40285]
40299 there is some evidence that an intravascular injection of thorium dioxide (Thorotrast) may be a factor in the development of the condition under consideration.
40300 the veteran has had an intravascular injection of thorium dioxide (Thorotrast) at some time.
40301 the veteran had an intravascular injection of thorium dioxide (Thorotrast) for treatment of an illness or injury which is identifiable.
40302 — the veteran has established the causal connection between an intravascular injection of thorium dioxide (Thorotrast) and VEA service for the clinical onset of mesothelioma.
40304 — the veteran has established the causal connection between an intravascular injection of thorium dioxide (Thorotrast) and eligible service for the clinical onset of mesothelioma.
or
40303 — the veteran has established the causal connection between an intravascular injection of thorium dioxide (Thorotrast) and operational service for the clinical onset of mesothelioma.
Clinical onset and operational service [40303]
for treatment of the identified illness or injury, the veteran had an intravascular injection of thorium dioxide (Thorotrast) at least ten years before the clinical onset of the condition under consideration.40307 — the identified illness or injury, for which the veteran had the intravascular injection of thorium dioxide (Thorotrast), is causally related to operational service.
Clinical onset and eligible service [40304]
for treatment of the identified illness or injury, the veteran had an intravascular injection of thorium dioxide (Thorotrast) at least 15 years before the clinical onset of the condition under consideration.40308 — the identified illness or injury, for which the veteran had the intravascular injection of thorium dioxide (Thorotrast), is causally related to eligible service.